Tag Archives: Vivera

MiniMed FY Q1 ’26 Earnings; Insulet Enhances O5 Algorithm and Integrates with Libre 3 Plus CGM; myLoop AID and Dexcom G7 CGM Integration Launches in EU

Three cardiometabolic-related news items have been observed: MiniMed hosted its CY Q1 ‘26 (FY Q4 ’26) earnings call (view press release; view slides); Insulet rolled out an updated O5 algorithm and expanded integration with Libre 3 Plus CGM (view press release); and CamDiab’s myLoop AID + Dexcom G7 CGM integration launched in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

MiniMed Flex Receives FDA Clearance; MetaVia Advances DA-1726 in Obesity; Ascletis Selects Another Obesity Candidate

Three cardiometabolic-related news items have been observed: MiniMed Flex received FDA clearance and launched its MiniMed Forward Program (view press release); MetaVia received IRB approval to advance DA-1726 in obesity (view press release); and Ascletis Pharma selected its oral amylin ASC39 as its next obesity candidate (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Retatrutide Risk Mitigation; Medtronic CY Q4 ’25 Earnings; 7.2mg Wegovy EU Approval; Lilly Targets India for Manufacturing Hub; EC Approval of Myqorzo; Esperion and Alkem Reach Generic BA Agreement

A series of cardiometabolic-related news items has been observed from Lilly, Medtronic, Novo Nordisk, Cytokinetics, and Esperion Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here